Association of a device-based remote management heart failure pathway with outcomes: TriageHF Plus real-world evaluation.
Cardiac implantable electronic devices
Heart failure
Hospitalization
Patient pathway
Remote monitoring
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
revised:
08
03
2024
received:
28
11
2023
accepted:
02
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
Clinical pathways have been shown to improve outcomes in patients with heart failure (HF). Although patients with HF often have a cardiac implantable electronic device, few studies have reported the utility of device-derived risk scores to augment and organize care. TriageHF Plus is a device-based HF clinical pathway (DHFP) that uses remote monitoring alerts to trigger structured telephone assessment for HF stability and optimization. We aimed to evaluate the impact of TriageHF Plus on hospitalizations and describe the associated workforce burden. TriageHF Plus was a multi-site, prospective study that compared outcomes for patients recruited between April 2019 and February 2021. All alert-triggered assessments were analysed to determine the appropriateness of the alert and the workload burden. A negative-binomial regression with inverse probability treatment weighting using a time-matched usual care cohort was applied to estimate the effect of TriageHF Plus on non-elective hospitalizations. A post hoc pre-COVID-19 sensitivity analysis was also performed. The TriageHF Plus cohort (n = 443) had a mean age of 68.8 ± 11.2 years, 77% male (usual care cohort: n = 315, mean age of 66.2 ± 14.5 years, 65% male). In the TriageHF Plus cohort, an acute medical issue was identified following an alert in 79/182 (43%) cases. Fifty assessments indicated acute HF, requiring clinical action in 44 cases. At 30 day follow-up, 39/66 (59%) of initially symptomatic patients reported improvement, and 20 (19%) initially asymptomatic patients had developed new symptoms. On average, each assessment took 10 min. The TriageHF Plus group had a 58% lower rate of hospitalizations across full follow-up [incidence relative ratio: 0.42, 95% confidence interval (CI): 0.23-0.76, P = 0.004]. Across the pre-COVID-19 window, hospitalizations were 31% lower (0.69, 95% CI: 0.46-1.04, P = 0.077). These data represent the largest real-world evaluation of a DHFP based on multi-parametric risk stratification. The TriageHF Plus clinical pathway was associated with an improvement in HF symptoms and reduced all-cause hospitalizations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : FS/19/34163
Pays : United Kingdom
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Heart Failure: A Blueprint for Change. British Heart Foundation; 2020. Available at URL: https://www.bsh.org.uk/wp‐content/uploads/2020/10/Heart‐Failure‐A‐Blueprint‐For‐Change‐Oct‐2020‐3.pdf. Accessed 9 July 2023
National Heart Failure Audit 2023 Summary Report. National Institute for Cardiovascular Outcomes Research (NICOR). Available at URL: https://www.nicor.org.uk/heart‐failure‐heart‐failure‐audit/. Accessed 9 July 2023
Action Statement on Heart Failure September 2021. The Heart Failure Policy Network. Available at URL: https://www.hfpolicynetwork.org/project/action‐statement‐on‐heart‐failure/. Accessed 9 July 2023
Donzé J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: Retrospective cohort study. BMJ: Brit Med J 2013;347:f7171. doi:10.1136/bmj.f7171
Cowie MR, Sarkar S, Koehler J, Whellan DJ, Crossley GH, Tang WHW, et al. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J 2013;34:2472‐2480. doi:10.1093/eurheartj/eht083
Brahmbhatt DH, Cowie MR. Remote management of heart failure: An overview of telemonitoring technologies. Card Fail Rev 2019;5:86‐92. doi:10.15420/cfr.2019.5.3
Taylor JK, Ahmed F. Clinical pathways guided by remotely monitoring cardiac device data: The future of device heart failure management? Arrhythmia Electrophysiol Rev 2023;12:e15. doi:10.15420/aer.2022.13
Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, et al. Implant‐based multiparameter telemonitoring of patients with heart failure (IN‐TIME): A randomised controlled trial. The Lancet 2014;384:583‐590. doi:10.1016/S0140‐6736(14)61176‐4
Hawkins NM, Virani SA, Sperrin M, Buchan IE, McMurray JJV, Krahn AD. Predicting heart failure decompensation using cardiac implantable electronic devices: A review of practices and challenges. Eur J Heart Fail 2016;18:977‐986. doi:10.1002/ejhf.458
Mohebali D, Kittleson MM. Remote monitoring in heart failure: Current and emerging technologies in the context of the pandemic. Heart 2021;107:366‐372. doi:10.1136/heartjnl‐2020‐318062
Whitelaw S, Pellegrini DM, Mamas MA, Cowie M, van Spall HGC. Barriers and facilitators of the uptake of digital health technology in cardiovascular care: A systematic scoping review. European Heart Journal‐Digital Health 2021;2:62‐74. doi:10.1093/ehjdh/ztab005
Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: Results from the MultiSENSE study. JACC: Heart Fail 2017;5:216‐225. doi:10.1016/j.jchf.2016.12.011
D'Onofrio A, Solimene F, Calò L, Calvi V, Viscusi M, Melissano D, et al. Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: Results from the SELENE HF study. EP Europace 2022;24:234‐244. doi:10.1093/europace/euab170
Treskes RW, Beles M, Caputo M‐L, Cordon A, Biundo E, Maes E, et al. Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients. ESC Heart Failure 2021;8:1541‐1551. doi:10.1002/ehf2.13252
Ahmed FZ, Taylor JK, Green C, Moore L, Goode A, Black P, et al. Triage‐HF Plus: A novel device‐based remote monitoring pathway to identify worsening heart failure. ESC heart failure 2020;7:108‐117. doi:10.1002/ehf2.12529
Burri H, Da Costa A, Quesada A, Ricci RP, Favale S, Clementy N, et al. Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. EP Europace 2018;20:e69‐e77. doi:10.1093/europace/eux206
Gula LJ, Wells GA, Yee R, Koehler J, Sarkar S, Sharma V, et al. A novel algorithm to assess risk of heart failure exacerbation using ICD diagnostics: Validation from RAFT. Heart Rhythm 2014;11:1626‐1631. doi:10.1016/j.hrthm.2014.05.015
Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk‐Hustings Y, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: A review of the literature. Arthritis Res Ther 2016;18:251. doi:10.1186/s13075‐016‐1151‐6
Gnanasakthy A, Barrett A, Norcross L, D'Alessio D, Romano CD. Use of patient and investigator global impression scales: A review of Food and Drug Administration‐approved labeling, 2009 to 2019. Value Health 2021;24:1016‐1023. doi:10.1016/j.jval.2021.01.005
National Institute for Health and Care Excellence. Chronic heart failure in adults: Diagnosis and management (NICE guideline NG106) 2018. https://www.nice.org.uk/guidance/ng106. Accessed 9 July 2023
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599‐3726. doi:10.1002/ejhf.2333
Shoaib A, van Spall H, Wu J, Cleland JGF, McDonagh T, Rashid M, et al. Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID‐19 pandemic. Eur Heart J—Qual Care Clin Outcomes 2021;7:378‐387. doi:10.1093/ehjqcco/qcab040
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available at URL: https://www.R‐project.org/. Accessed 9 July 2023
Brugts JJ, Radhoe SP, Clephas PR, Aydin D, Van Gent MW, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR‐HF): A randomised clinical trial. Lancet 2023;401:2113‐2123. doi:10.1016/S0140‐6736(23)00923‐6
Kul S, Barbieri A, Milan E, Montag I, Vanhaecht K, Panella M. Effects of care pathways on the in‐hospital treatment of heart failure: A systematic review. BMC Cardiovasc Disord 2012;12:81. doi:10.1186/1471‐2261‐12‐81
Dierckx R, Inglis SC, Clark RA, Prieto‐Merino D, Cleland JGF. Telemedicine in heart failure: New insights from the Cochrane meta‐analyses. Eur J Heart Fail 2017;19:304‐306. doi:10.1002/ejhf.759
Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez‐Cabanillas N, Abe H, et al. HRS/EHRA/APHRS/LAHRS expert consensus statement on practical management of the remote device clinic. EP Europace 2023;25: doi:10.1093/europace/euad123
Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T, et al. Improving care for patients with acute heart failure: Before, during and after hospitalization. ESC Heart Failure 2014;1:110‐145. doi:10.1002/ehf2.12021
Tsuyuki RT, McKelvie RS, Arnold JMO, Avezum A Jr, Barretto AC, Carvalho AC, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337‐2342. doi:10.1001/archinte.161.19.2337